🇺🇸 FDA
Pipeline program

T cell injection targeting CD7 chimeric antigen receptor

PA-CART-3-17-001

Unknown small_molecule active

Quick answer

T cell injection targeting CD7 chimeric antigen receptor for T-ALL is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
T-ALL
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials